Award Number: DAMD17-96-1-6022

TITLE: The Role of PKC in Retinoic Acid Regulation of Human Mammary Cancer Cell Proliferation

PRINCIPAL INVESTIGATOR: Yunhi Cho, Ph.D.
David A. Talmage, Ph.D.

CONTRACTING ORGANIZATION: Columbia University
New York, New York 10032

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
The Role of PKC in Retinoic Acid Regulation of Human Mammary Cancer Cell Proliferation

Yunhi Cho, Ph.D.
David A. Talmage, Ph.D.

Columbia University
New York, New York 10032

E-MAIL: datl@columbia.edu

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for public release; distribution unlimited

Breast Cancer, retinoids, vitamin A, protein kinase Ca

Unclassified

NSN 7540-01-280-5500
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature 1/1/00 Date
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Front Cover</td>
<td>1</td>
</tr>
<tr>
<td>Standard Form (SF) 298</td>
<td>2</td>
</tr>
<tr>
<td>Foreword</td>
<td>3</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>4</td>
</tr>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>Body</td>
<td>5</td>
</tr>
<tr>
<td>Appendices</td>
<td>7</td>
</tr>
</tbody>
</table>
INTRODUCTION

Retinoids have anti-tumor effects and a number of clinical trials of retinoids in human breast cancer have been initiated. Although retinoids inhibit proliferation of numerous breast cancer cell lines, responsiveness appears to be limited to estrogen-dependent cells, in which retinoic acid (RA) inhibits estrogen stimulation of proliferation. The proliferative effect of estrogen on mammary cells has been linked to the production of mitogenic growth factors and increased expression of surface receptor tyrosine kinases. Growth factor binding to receptor tyrosine kinases activates multiple, interactive signaling pathways, most of which involve sequential activation of serine/threonine protein kinases. Retinoic acid (RA) inhibits signaling between receptor tyrosine kinases and the nucleus. The components of these signaling pathways that serve as targets for RA have yet to be identified. At least two signaling pathways stimulated by receptor tyrosine kinase utilize protein kinase C (PKC) family members as mediators. Because of the relationships between hormone-dependent mammary cell proliferation, RA growth regulation and protein kinase C, we have hypothesized that retinoic acid inhibits the uncontrolled proliferation of mammary carcinoma cells, by increasing the overall activity of PKC_{alpha}, and/or decreasing the overall activity of PKC_{zeta}. Two HBC cell lines are used in our study, the hormone-dependent/RA-sensitive T47D cell line and the hormone-independent/RA-resistant MDA-MB-231 line.

BODY

Overview. This award, DAMD17-96-1-6022, provided support for post-doctoral training of Dr. Yunhi Cho. The research proposal was divided into two specific aims that were to be completed by performing four tasks. Tasks 1-3 were completed in Years 1 & 2 and the results have been reported in past annual reports. Task 4 was begun in Year 2 and completed in Year 3. One paper describing these results has been published and 2 additional manuscripts will be submitted within the next 4 weeks. In addition Dr. Cho presented her data at a lecture to the Food and Nutrition Research Institute of EWHA Women's University (proceedings published as: Cho, Y. and Talmage, D.A. The role protein kinase C in anti-cancer mechanism of retinoic acid. Foods and Nutrition Proceedings, vol. 8, Department of Foods and Nutrition, Asia Food and Nutrition Research Institute, EWHA Women's University, Seoul Korea. 1998, pp. 63-80), at the 8th Asian Congress of Nutrition in Seoul, Korea (Aug 29 – Sept. 2, 1999) and will present it at an upcoming Keystone Symposium (Protein Kinase C: Structure, Regulation and Cellular Function, 2/5/00 – 2/10/00). At the end of the training period (September 1, 1999) Dr. Cho was promoted to the position of Associate Research Scientist, a research track faculty position at Columbia University. As of March 1, 2000 Dr. Cho will become Assistant Professor of Nutritional Biochemistry at the Graduate School of East-West Medical Science, Kyung Hee University in Korea. On the whole, I think that it is clear that this training fellowship has been enormously successful.

Detailed Report on Scientific Progress. Progress on Task 1: Characterization of cell lines for expression, translocation and activity of PKC isozymes. Two parental cell lines have been compared. One is hormone-dependent and retinoid sensitive (T47D cells), the other is hormone-independent and retinoid resistant (MDA-MB-231 cells). PKC expression patterns were analyzed by a combination of northern blot and immunoblot analyses. These results have been published in Cho et al., J. Cellular Physiology, 1997, 172:306-313.
Table 1. Expression of PKC isozymes in human breast cancer cells.

<table>
<thead>
<tr>
<th>PKC Isozyme</th>
<th>T47D -RA</th>
<th>T47D +RA</th>
<th>MDA-MB-231 -RA</th>
<th>MDA-MB-231 +RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKCα</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>PKCβ</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PKCε</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>PKCδ</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>PKCγ</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Note: Changes in PKCα were seen within 24 hr of RA treatment of T47D cells whereas changes in PKCε levels were not seen until 5+ days of RA treatment. No significant differences in the expression of PKCδ or PKCε were seen under any conditions.

Based on the above results future experiments focussed on the role of PKCα.

Progress on Task 2: Characterization of cell lines for proto-oncogene expression. We used northern blot analyses to characterize the expression of 6 proto-oncogenes in response to mitogenic stimulus of T47D and MDA-MB-231 cells both in the absence and presence of RA. Estrogen, epidermal growth factor (EGF), insulin and fetal bovine serum rapidly induced expression of c-myc, c-fos, fosB, c-jun and junB but not junD in T47D cells. Prior treatment with RA (>12 hours) reduced induction in each case by 60-80%. EGF was significantly more potent at inducing expression of these genes than other agents tested. Only fetal bovine serum effectively induced expression of these target genes in MDA-MB-231 cells. RA pretreatment had no effect on fbs induction of any gene examined except for junB. RA pretreatment reduced junB induction by 3 fold. These results are described in: Tighe, A.P., Cho, Y. and Talmage, D.A. Retinoic acid inhibits human breast cancer cell proliferation by attenuating epidermal growth factor signaling. Manuscript submitted to Mol. Cell. Biol., Jan., 2000.

Progress on Task 3: Characterization of retinoic acid effect on cell cycle progression. Retinoids inhibit proliferation of T47D cells in a time and dose dependent manner. At 10^{-6} M, RA inhibited proliferation within 24 hr, at 10^{-9} M inhibition was maximal at 72 hr. Retinoids at any concentration tested, had no effect on proliferation of MDA-MB-231 cells. Retinoic acid inhibition of T47D cell proliferation was the apparent result of a loss of mitogenic signaling resulting in cells reversibly entering a G_0-like phase of the cell cycle. These results are also reported in Tighe, A.P., Cho, Y. and Talmage, D.A. Retinoic acid inhibits human breast cancer cell proliferation by attenuating epidermal growth factor signaling. Manuscript submitted to Mol. Cell. Biol., Jan., 2000.

Progress on Task 4: Manipulation of individual PKC isozyme gene expression. T47D cells. PKCα was constitutively expressed in T47D cells. The resultant cell line, αT47D grew poorly (at a rate roughly equivalent to parental cells treated with 10^{-9} M RA). Inhibition of PKCα activity in both αT47D cells and in RA treated T47D cells returned proliferation rates to control levels. Therefore the anti-proliferative effect of retinoids on these cells was mediated by the retinoid induced gene product, PKCα. This result has been published (Cho et al., J. Cellular Physiology, 1997, 172:306-313). The role of PKCα as a mediator of retinoid action is conclusively supported by results of extensive comparative analysis of the effects of retinoid and constitutive PKCα expression on EGF signaling (± a PKCα inhibitor). These latter studies were not carried out by Dr. Cho but are
reported in a manuscript on which she is a co-author (Tighe, A.P., Cho, Y. and Talmage, D.A. Retinoic acid inhibits human breast cancer cell proliferation by attenuating epidermal growth factor signaling. Submitted).

**MDA-MB-231 cells.** PKCα was constitutively expressed in MDA-MB-231 cells. PKCα expression had no effect on MDA-MB-231 cell proliferation rates. PKCα expression also failed to affect the ability of fetal bovine serum to induce expression of c-fos, c-jun or fosB. PKCα expression marginally reduced serum induction of junB mRNA levels. What PKCα expression in MDA-MB-231 cells did do, was to confer sensitivity to retinoids. Thus, although RA had no effect on MDA-MB-231 proliferation or serum signaling, RA treatment did inhibit the proliferation of PKCα expressing MDA-MB-231 cells and inhibited fetal bovine serum induction of c-fos and junB. RA treatment also increased PKCα levels in these cells. Recent experiments demonstrate that this increase was the result of increasing the half-life of active PKCα. The mechanism for this effect is not known. These results are reported in: Cho, Y. and Talmage, D.A. Protein kinase Cα expression confers retinoic acid sensitivity in MDA-MB-231 human breast cancer cells. Manuscript submitted to Mol. Cell. Biol., Jan., 2000.

**APPENDED MATERIAL.**

**Key accomplishments.**
- Demonstrated that retinoids induce expression of PKCα
- Demonstrated that PKCα activity is required for retinoids to arrest proliferation of hormone dependent, human breast cancer cells
- Demonstrated that PKCα inhibits mitogenic signaling from receptor tyrosine kinases to promoters of selected proto-oncogenes
- Demonstrated that PKCα can confer retinoid sensitivity on hormone-independent, retinoid-resistant, human breast cancer cells
- Demonstrated that retinoids can prevent down-regulation of active PKCα

**Reportable outcomes.**

**Manuscripts etc.:**


⇒ Cho, Y. and Talmage, D.A. Protein kinase Cα expression confers retinoic acid sensitivity in MDA-MB-231 human breast cancer cells. Keystone Symposia on Molecular and Cellular

7
Biology, “Protein Kinase C: Structure, Regulation and Cellular Function. Taos, NM. 2/5/00 – 2/10/00.

Patents.
None.

Degrees obtained.
None.

Cell lines developed.
αT47D – T47D human breast cancer cells, constitutively expressing PKCα and resistance to G418.
αMDA – MDA-MB-231 human breast cancer cells constitutively expressing PKCα and hygromycin resistance.
OPR-PKCα-MDA – MDA-MB-231 human breast cancer cells constitutively expressing the bacterial lac I gene and both hygromycin and G418 resistance. In addition these cells reversibly express PKCα following addition of IPTG to the culture media.

Informatics.
None.

Funding applied for.
None, yet. NIH R01 application is being prepared.

Employment.
Dr. Cho has accepted a position as an Assistant Professor in the Department of Nutritional Biochemistry at the Graduate School of East-West Medical Science, Kyung Hee University, Korea.